Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding

Oncotarget

Volumn 5, Issue 12, 2014, Pages 4492-4503

  Agyeman, Akwasi ^a   Jha, Babal K ^a   Mazumdar, Tapati ^a   Houghton, Janet A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GANT 61; KRUPPEL LIKE FACTOR 4; LUCIFERASE; SELUMETINIB; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR IIB; UNCLASSIFIED DRUG; VISMODEGIB; GLI1 PROTEIN, HUMAN; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL DEATH; CELL SURVIVAL; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MUTATION; PROTEIN DNA BINDING; SURFACE PLASMON RESONANCE; COLON TUMOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; HEDGEHOG PROTEINS; HUMANS; PYRIDINES; PYRIMIDINES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84905107941     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2046     Document Type: Article

References (70)

1. Katoh Y, & Katoh M, Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 2009; 9: 873-886.
2. Yu M, Gipp J, Yoon JW, Iannaccone P, Walterhouse D, Bushman W, Sonic hedgehog-responsive genes in the fetal prostate. J Biol Chem 2009; 284:5620-5629.
3. Hooper JE, Scott MP, Communicating with Hedgehogs. Nat Rev Mol Cell Biol 2005; 6:306-317.
4. Varnat F, Zacchetti G, Ruiz i Altaba A, Hedgehog pathway activity is required for the lethality and intestinal phenotypes of mice with hyperactive Wnt signaling. Mech Dev 2005: 127:73-81.
5. Alinger B, Kiesslich T, Datz C, Aberger F, Strasser F, Berr F, Dietze O, Kaserer K, Hauser-Kronberger C, Hedgehog signaling is involved in differentiation of normal colonic tissue rather than in tumor proliferation. Virchows Arch 2009; 454:369-379.
6. Kinzler KW, Ruppert JM, Bigner SH, Vogelstein B, The GLI gene is a member of the Kruppel family of zinc finger proteins. Nature 1988; 332:371-374.
7. Kasper M, Schnidar H, Neill GW, Hanneder M, Klingler S, Blaas L, Schmid C, Hauser-Kronberger C, Regl G, Philpott MP, Aberger F, Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol Cell Biol 2006; 26:6283-6298.
8. Thiyagarajan S, Bhatia N, Reagan-Shaw S, Cozma D, Thomas-Tikhonenko A, Ahmad N, Spiegelman VS, Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells. Cancer Res 2007; 67:10642-10646.
9. Ikram MS, Neill GW, Regl G, Eichberger T, Frischauf AM, Aberger F, Quinn A, Philpott M. GLI2 is expressed in normal human epidermis and BCC and induces GLI1 expression by binding to its promoter. J Invest Dermatol 2004: 122:1503-1509.
10. Bai CB, Auerbach W, Lee JS, Stephen D, Joyner AL, Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development 2002; 129:4753-4761.
11. Eichberger T, Sander V, Schnidar H, Regl G, Kasper M, Schmid C, Plamberger S, Kaser A, Aberger F, Frischauf AM, Overlapping and distinct transcriptional regulator properties of the GLI1 and GLI2 oncogenes. Genomics 2006; 87:616-632.
12. Mill P, Mo R, Fu H, Grachtchouk M, Kim PC, Dlugosz AA, Hui CC, Sonic hedgehog-dependent activation of Gli2 is essential for embryonic hair follicle development. Genes Dev 2003; 17:282-294.
13. Roessler E, Du YZ, Mullor JL, Casas E, Allen WP, Gillessen-Kaesbach G, Roeder ER, Ming JE, Ruiz i Altaba A, Muenke M, Loss-of-function mutations in the human GLI2 gene are associated with pituitary anomalies and holoprosencephaly-like features. Proc Natl Acad Sci U S A 2003; 100:13424-13429.
14. Ruiz i Altaba A, Mas C, Stecca B, The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 2007; 17:438-447.
15. Kinzler KW, Bigner SH, Trent JM, Law ML, O'Brien SJ, Wong AJ, Vogelstein B, Identification of an amplified, highly expressed gene in a human glioma. Science 1987; 236:70-73.
16. Kasper M, Regl G, Frischauf AM, Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur J Cancer 2006; 42:437-445.
17. Zhang D, Cao L, Li Y, Lu H, Yang X, Xue P, Expression of glioma-associated oncogene 2 (Gli 2) is correlated with poor prognosis in patients with hepatocellular carcinoma undergoing hepatectomy. World J Surg Oncol 2013; 11-25.
18. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, Beermann F, Ruiz I Altaba A, Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A 2007; 104:5895-5900.
19. Sanchez P, Hernández AM, Stecca B, Kahler AJ, DeGueme AM, Barrett A, Beyna M, Datta MW, Datta S, Ruiz i Altaba A, Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A 2004; 101:12561-12566.
20. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A, Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 2009; 1:338-351.
21. Ecke I, Rosenberger A, Obenauer S, Dullin C, Aberger F, Kimmina S, Schweyer S, Hahn H, Cyclopamine treatment of full-blown Hh/Ptch-associated RMS partially inhibits Hh/Ptch signaling, but not tumor growth. Mol Carcinog 2008; 47:361-372.
22. Sarangi A, Valadez JG, Rush S, Abel TW, Thompson RC, Cooper MK, Targeted inhibition of the Hedgehog pathway in established malignant glioma xenografts enhances survival. Oncogene 2009; 28:3468-3476.
23. Mas C, Ruiz i Altaba A, Small molecule modulation of HH-GLI signaling: current leads, trials and tribulations. Biochem Pharmacol 2010; 80:712-723.
24. Robarge KD, Brunton SA, Castanedo GM, Cui Y, Dina MS, Goldsmith R, Gould SE, Guichert O, Gunzner JL, Halladay J, Jia W, Khojasteh C, Koehler MF, Kotkow K, La H, Lalonde RL, Lau K, Lee L, Marshall D, Marsters JC Jr, Murray LJ, Qian C, Rubin LL, Salphati L, Stanley MS, Stibbard JH, Sutherlin DP, Ubhayaker S, Wang S, Wong S, Xie M. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009; 19:5576-5581.
25. Low JA, de Sauvage FJ, Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010; 28:5321-5326.
26. De Smaele E, Ferretti E, Gulino A, Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Investig Drugs 2010; 11:707-718.
27. Lorusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad M., Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von HoffDD, Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res 2011; 17:2502-2511.
28. Von HoffDD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC, de Sauvage FJ, Low JA, Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009; 361:1164-1172.
29. Dierks C. GDC-0449--targeting the hedgehog signaling pathway. Recent Results Cancer Res 2010; 184:235-238.
30. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von HoffDD, de Sauvage FJ, Low JA, Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173-1178.
31. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ, Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326:572-574.
32. Yoshikawa K, Shimada M, Miyamoto H, Higashijima J, Miyatani T, Nishioka M, Kurita N, Iwata T, Uehara H, Sonic hedgehog relates to colorectal carcinogenesis. J Gastroenterol 2009; 44:1113-1117.
33. Bian YH, Huang SH, Yang L, Ma XL, Xie JW, Zhang HW, Sonic hedgehog-Gli1 pathway in colorectal adenocarcinomas. World J Gastroenterol 2007; 13:1659-1665.
34. Shi T, Mazumdar T, DeVecchio J, Duan ZH, Agyeman A, Aziz M, Houghton JA. cDNA microarray gene expression profiling of hedgehog signaling pathway inhibition in human colon cancer cells. PloS one 2010; 5, e13054.
35. Mazumdar T, DeVecchio J, Shi T, Jones J, Agyeman A, Houghton JA, Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res 2010; 71: 1092-1102.
36. Mazumdar T, Devecchio J, Agyeman A, Shi T, Houghton J.A, Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res 2011; 71:5904-5914.
37. Mazumdar T, DeVecchio J, Agyeman A, Shi T, Houghton JA, The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer. Oncotarget 2011; 2:638-645.
38. Agyeman A, Mazumdar T, Houghton JA, Regulation of DNA Damage Following Termination of Hedgehog (HH) Survival Signaling at the level of the GLI Genes in Human Colon Cancer. Oncotarget 2010; 3:854-868.
39. Yoon JW, Kita Y, Frank DJ, Majewski RR, Konicek BA, Nobrega MA, Jacob H, Walterhouse D, Iannaccone P, Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J Biol Chem 2002; 277:5548-5555.
40. Schnidar H, Eberl M, Klingler S, Mangelberger D, Kasper M, Hauser-Kronberger C, Regl G, Kroismayr R, Moriggl R, Sibilia M, Aberger F, Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res 2009; 69:1284-1292.
41. Lauth M, Toftgard R, Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. Cell Cycle 2007; 6:2458-2463.
42. Yoon S, Seger R, The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006; 24:21-44.
43. Little AS, Smith PD, Cook SJ, Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene 2012; 32:1207-1215.
44. Ji Z, Mei FC, Xie J, Cheng X, Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 2007; 282:14048-14055.
45. Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD, Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther 2011; 10:336-346.
46. Tentler JJ, Nallapareddy S, Tan AC, Spreafico A, Pitts TM, Morelli MP, Selby HM, Kachaeva MI, Flanigan SA, Kulikowski GN, Leong S, Arcaroli JJ, Messersmith WA, Eckhardt SG, Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol Cancer Ther 2010; 9:3351-3362.
47. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008; 68:6145-6153.
48. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765.
49. Hingorani SR, Jacobetz MA, Robertson GP., Herlyn M, Tuveson DA, Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003; 63:5198-5202.
50. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, Whitehall VL, Leggett BA, Laird PW, Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PloS one 2009; 4: e8357.
51. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL, American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091-2096.
52. Mercer KE, Pritchard CA, Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003; 1653:25-40.
53. Lauth M, Bergstrom A, Shimokawa T, Toftgard R, Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A 2007; 104:8455-8460.
54. Pavletich NP, Pabo CO, Crystal structure of a five-finger GLI-DNA complex: new perspectives on zinc fingers. Science 1993; 261:1701-1707.
55. Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira S.-M. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PloS One 2012; 7: e44146.
56. Ruppert JM, Kinzler, KW, Wong AJ, Bigner SH, Kao FT, Law ML, Seuanez HN, O'Brien SJ, Vogelstein B, The GLI-Kruppel family of human genes. Mol Cell Biol 1988; 8:3104-3113.
57. Day YS, Baird CL, Rich RL, Myszka DG, Direct comparison of binding equilibrium, thermodynamic, and rate constants determined by surface- and solution-based biophysical methods. Protein Science: A Publication of the Protein Society 2002; 11:1017-1025.
58. Thurmond RL, Wadsworth SA, Schafer PH, Zivin, RA, Siekierka JJ, Kinetics of small molecule inhibitor binding to p38 kinase. Eur J Biochem/FEBS 2001; 268:5747-5754.
59. Sordet O, Nakamura AJ, Redon CE, Pommier Y. DNA double-strand breaks and ATM activation by transcription-blocking DNA lesions. Cell Cycle 2010; 9:274-278.
60. Sordet O, Redon CE, Guirouilh-Barbat J, Smith S, Solier S, Douarre C, Conti C, Nakamura AJ, Das BB, Nicolas E, Kohn KW, Bonner WM, Pommier Y, Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep 2009; 10:887-893.
61. Tiwari N, Meyer-Schaller N, Arnold P, Antoniadis H, Pachkov M, van Nimwegan E, Christofori G, Klf4 is a transcriptional regulator of genes critical for EMT, including Jnk1 (Mapk8). PloS one 2013; 8: e57329.
62. Elsby LM, Roberts SG, Interaction of the TFIIB zinc ribbon with RNA polymerase II. Biochem Soc Trans 2008; 36:595-598.
63. Saif MW, Chu E, Biology of colorectal cancer. Cancer J 2010; 16:196-201.
64. Siegel R, Naishadham D, Jemal A, Cancer Statistics, 2012. CA: A Cancer Journal For Clinicians 2012; 62:10-29.
65. Thakur CS, Jha BK, Dong B, Das Gupta J, Silverman KM, Mao HS, Sawai H, Nakamura AO, Banerjee AK, Godkov A, Silverman, RH, Small-molecule activators of RNase L with broad-spectrum antiviral activity. Proc Natl Acad Sci U S A 2007; 104:9585-9590.
66. Lauth M, Rohnalter V, Bergstrom A, Kooshesh M, Svenningsson P, Toftgard R, Antipsychotic drugs regulate hedgehog signaling by modulation of 7-dehydrocholesterol reductase levels. Mol Pharmacol 2010; 78:486-496.
67. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605-1612.
68. Sheffield P, Garrard S, Derewenda Z, Overcoming expression and purification problems of RhoGDI using a family of "parallel" expression vectors. Protein expression and purification 1999; 15:34-39.
69. Nieba L, Nieba-Axmann SE, Persson A, Hämäläinen M, Edebratt F, Hansson A, Lidholm J, Magnusson K, Karlsson AF, Plückthun A. BIACORE analysis of histidine-tagged proteins using a chelating NTA sensor chip. Analytical Biochemistry 1997; 252:217-228.
70. Kogerman P, Grimm T, Kogerman L, Krause D, Undén AB, Sandstedt B, Toftgård R, Zaphiropoulos PG, Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. Nature Cell Biol 1999; 1:312-319.